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Summary Fifty-five patients with inoperable but limited stage small cell carcinoma of the bronchus and a
further 15 patients with contra lateral neck nodes, pleural effusions and marrow involvement were entered
into the study and treated.
The 3 month treatment regimen comprised 3 courses of etoposide with cyclophosphamide at 2.5gm-2
followed by methotrexate and radiotherapy, no maintenance treatment was given. The complete response rate
in the total patient group was 54% and the partial response rate 21%.
The median survival was 11 months for the 70 patients, 15 months for the complete responders, and those
patients with a bronchoscopically confirmed complete response survived significantly longer, There was no
significant difference between the patients with strictly limited stage disease and those in the broader category.
Eight patients are tumour free and alive one year or more after the end of treatment. The median followup is
17 months.
Twenty-four patients were delayed 1-2 weeks during treatment because of chemotherapy induced toxicity.
Six patients died probably of infection associated with leucopaenia. The majority of the patients' Karnofsky
performance improved with the treatment as did their breathlessness assessed on a respiratory score.
The short intensive chemotherapy regimen of 3 months produced similar results to those following more
prolonged treatment regimens.
Combination chemotherapy for small cell lung
cancer now produces a 70% or more response rate
(Greco et al., 1981; Straus et al., 1983). There has
been a corresponding increase in median survival,
but only 10-20% of patients with limited stage
disease are alive and tumour free beyond two years
(Greco et al., 1981; Hansen & Roth, 1983; Oldham
& Greco, 1980; Straus et al., 1983).
It has been customary to give prolonged chemo-
therapy for up to 12-18 months especially to
patients who exhibit complete responses (Greco et
al., 1981; Hansen & Roth, 1983; Straus et al.,
1983). The Manchester Lung Tumour Group
(MLTG) and others have reported favourable
results of short but intensive chemotherapy, lasting
only a few months (Baaker et al., 1984; Thatcher et
al., 1982a, 1984b) Maintenance chemotherapy has
been assessed recently by several groups and it
would appear to confer no additional benefit to the
patients with limited disease (Baaker et al., 1984;
Cullen et al., 1983; Woods et al., 1983).
It was therefore decided to investigate further an
intensive but short duration chemotherapy regimen
followed by thoracic radiotherapy. On the basis of
previous work a dose of cyclophosphamide
(2.5 g m2) was chosen. Tumour responses with
higher doses were uncommon and were associated
with increasingly severe haematological toxicity
(Thatcher et al., 1982a,b; 1984a,b) especially when
used in combination with etoposide. The present
report of a different patient group describes the
results of a three month treatment with cyclophos-
phamide used at the higher dose (2.5gm2) than
the standard (_ 1.0 gm-2) with etoposide followed
by methotrexate and radiotherapy to the local
thoracic tumour mass.
The use of methotrexate followed by thoracic
irradiation was an attempt to improve tumour
control (Pointon et al., 1983; Spittle, 1978).
Patients and methods
Seventy patients with histologically proven,
inoperable small cell bronchogenic carcinoma and
previously untreated were considered eligible for the
study. Patients were assessed by routine history,
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clinical examination, Karnofsky and respiratory
score, complete blood count, biochemistry including
creatinine, urea and electrolytes, liver function tests,
bone marrow aspirate and trephine; radionuclide
and ultrasound scans were done to confirm clinical
and biochemical abnormalities suggestive of meta-
static disease. Diagnosis was made from biopsy
specimens.
Limited disease (55 patients) was defined as
inoperable tumour confined to one hemithorax but
including mediastinal extension and ipsilateral
supraclavicular lymphadenopathy. Fifteen other
patients with contralateral supraclavicular
adenopathy, ipsilateral pleural effusions, superior
vena caval obstruction, or with marrow infiltration
were also considered eligible for the study.
However, patients with clinical or radiological
evidence of metastases in other sites (brain, liver,
etc.) were excluded from the study. There were 42
male and 28 female patients. The median age of the
patient group was 59 years (range 23-70). All but 6
patients were cigarette smokers of 5-50 per day
(median 20) for 10-50 years (median 30 years).
Further clinical details as given in Table I.
Treatment protocol
Patients were treated with three courses at three
weekly intervals of cyclophosphamide and
etoposide. Each course comprised cyclophos-
phamide 2.5gm-2 (day 1) with etoposide
120 mgm-2 i.v. days 1 and 2 and 240mgm-2
orally on the 3rd day. The cyclophosphamide doses
were given as i.v. bolus injections followed by
1.51m-2 normal saline over 24h. Three weeks after
the third cyclophosphamide and etoposide course,
methotrexate 1OOmgm-2 i.v. (day 64), was
administered, repeated 14 days later and followed
the next day by thoracic irradiation. Radiotherapy
(4MeV) was given to encompass the known
thoracic disease present before chemotherapy, being
delivered in 8 fractions over 10 days to 3250cGy,
max skin dose (3000cGymin tumour dose) through
AP and PA portals. Folinic acid was prescribed if
the 24h serum methotrexate level was
> 115ngml-P.
Before each course of treatment patients were
assessed by routine history, clinical examination,
Karnofsky and respiratory scores, complete blood
count, biochemistry and chest X-rays. If the white
cell count was <2500cellsul-1 and/or the platelet
count was <75,000cells u1l-1, therapy was delayed
by a week until recovery to above these values
(checked weekly). Patients were advised to contact
the hospital if they felt unwell between chemo-
therapy courses, and appropriate investigations
were then undertaken. If the disease progressed, the
treatment protocol was discontinued and
symptomatic measures instituted.
Table I Clinical features in 70 patients before treatment.
Male:-female 42:28
Superior vena caval obstruction 12
Weight loss (10% over 6 months) 39
Interval from symptoms to diagnosis
1-3 months 49
3-6 months 18
6 months 3
Interval from diagnosis to treatment
l month 64
1-2 months 5
2 months 1
Sites ofprimary neoplasm
R:L 37:33
Lymphadenopathy
ipsilateral SCF 15
contralateral SCF 5
hilar 69
mediastinal 55
Pleural effusion (positive cytology) 15
Marrow deposit 7
Inappropriate ADH secretion (on biochemistry) 10
Raised alkaline phosphatasea 20
Raised lactate dehydrogenasea 18
Raised ALT, and or GT' 16
Normal enzymes 33
ALT=alanine aminotransferase. GT=glutamyl
transpeptidase. aThese patients had no evidence (by
scanning) ofmetastatic disease before treatment.
Follow-up
After the end of radiotherapy, patients were seen
monthly for 4 months then every 3 months for a
year, and every 6 months thereafter. Routine blood
counts, biochemistry and chest X-ray were repeated
at each visit and more frequent or additional
investigations were done as clinically indicated.
Assessment for evidence of objective response was
undertaken at the first follow-up visit (a month
after radiotherapy), determined by the standard
UICC criteria (Monfardini et al., 1981) and repeat
bronchoscopy was performed when possible.
Toxicity, Karnofsky performance and respiratory
scores (MRC Lung Cancer Working Party, 1979)
were recorded after each course of chemotherapy
and one month after radiotherapy. The median
follow up time is 17 months.
Results
No patient has been excluded from the analysis
because of incomplete treatment, early death,
toxicity, etc. Thirty-eight patients, 54% of the total
study group, had a complete tumour response when
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Table II Change in Karnofsky performance (KP) scale
and respiratory assessment score (RAS) with treatment.
Initial Post CTPost CTPost CT
KP score score 1 2 3 Post XRT
50
50-70
80-100
11
58
1
5
41
24
9
19
42
10
8
52
l lb
9
50a
a33 patients were noted to have a KP of 90 or more at
the end of treatment.
RAS score
1,2
3,4
5
3 20 30 48
56 44 31 12
11 6 9 10
s3c
6
l lb
Grade 1,2 climb hills, stairs, walk any distance on the
flat at normal pace, without dyspnoea: Grade 3,4 walk
more than 100 yards at own speed without dyspnoea,
dyspnoea on walking 100 yards or less: Grade 5 dyspnoea
on mild exertion, e.g. undressing (dying patients included).
bIncluding the 10 early deaths. cTwenty patients had
normal exercise tolerance at end of treatment.
fibreoptic bronchoscopy was performed when
possible to document further the complete response.
In 26 patients the complete response status was
confirmed. The 3 other patients who underwent
repeated bronchoscopy had suspicious findings but
equivocal biopsies. The majority of complete
responses (32) were noted radiologically on the
chest X-ray taken at the time of the first injection
of methotrexate. A further 15 patients (21%)
obtained a partial response. The median duration
of response was 8 months (range 4-18); median
duration of complete response was 9 months and of
partial response, 6 months. The Karnofsky
performance score improved with treatment as did
the respiratory score (Table II).
Thirty-seven patients relapsed, 10 died before
completing treatment, one died in clinically
complete response 6 weeks after the end of radio-
therapy, 14 are alive with no evidence of tumour,
one continues in partial response and the remaining
7 did not not respond to treatment.
Of the 37 patients who relapsed, 14 were
complete responders who have died, 9 were
complete responders who are alive but in relapse
and the other 14 were patients who had a partial
response of whom 3 are alive. The distribution of
relapse sites is shown in Table III. The distant sites
of solitary metastases are also shown but of the
complete responder patients who did not relapse
locally (within or immediately adjacent to irradiated
zone), 5 patients have developed brain metastases
and 3 patients metastases to soft tissue, bone and
neck nodes respectively. Chemotherapy (ifosfamide)
was given to 19% and palliative radiotherapy to
25% of the relapsed patients.
Table III Distribution of relapse sites.
Complete Partial
responders responders
(23) (14)
Local only 5 2
Distant only 10 6
Both local and distant 8 6
Sites ofdistant relapse
Complete Partial
responders responders
Nodes: cervical/SCF 4 (1) 3
upper abdo. 2 (1)
Opposite lung 1 1
Brain 9 (5) 5 (3)
Liver 4 3 (1)
Bone 3 (1) 1 (1)
Soft tissue 4 (1) I
Patients without local relapse in primary tumour area
but with SINGLE sites of metastasis indicated in ( ).
0- 6(A
0
>51
n)
;(17)
Time (months)
Figure 1 Survival according to response.
Survival
Eighteen patients are alive a year or more from the
start of chemotherapy (Figure 1), 8 of whom
continue in complete response. The one year
survival of all 70 patients is 48% and the 18-month
actuarial survival is 35%.
For the 38 patients classed as complete
responders, the one year and 18-month survival
figures were 66% and 52%; when complete
response was confirmed at repeat bronchoscopy,
the corresponding figures were 76% and 68%. The
corresponding values for the patients who did not330 N. THATCHER et al.
achieve complete response were 30% and 0%
respectively (but the longest PR survivor is alive at
16 months).
The median survival of all 70 patients was 11
months, (range 1-18), and of the complete
responders, 15 months. Survival was significantly
longer (P=0.00001 log rank chi square analysis)
for the complete responders compared with the
other patients (Figure 1). The survival of the 26
patients whose complete response was confirmed on
repeat bronchoscopy was also significantly longer
(P=0.0001) than for the other patients, and the
complete responders assessed only clinically and
radiologically.
The median survival for the 55 patients with
conventional 'limited stage' disease was 12 months
(range 1-18). There was no statistically significant
difference (P=0.12) between these 55 patients and
the other 15 patients included within the wider
stage definition. Survival from observation of
relapse was poor with a median value of two
months (range 1-9 months).
Toxicity
Sixty patients completed the planned treatment
programme. Five patients received the first course
only of cyclophosphamide and VP16-213, 4 patients
received two courses and the remaining patient had
the third course but not the methotrexate. Four
patients died of presumed infection associated with
leucopaenia, <1000cellsyul-1, and in a further two
patients positive blood cultures were reported.
Three of the patients died after the first course, two
after the second and one after the third course of
cyclophosphamide and VP16-213. The other 4
patients who did not complete treatment died of
tumour.
Leucopaenia of < 1000cellsml1 was observed
in 10 patients after the first course of
chemotherapy, 9 patients after the second and 8
patients after the third course; parental antibiotics
were given on 25 occasions. Four of the patients
had perianal abscesses. Blood transfusions were
given on 36 occasions and platelet transfusions on 5
occasions. Folinic acid was prescribed for 12
patients. Twenty-four patients had a delay of 1-2
weeks during one of the 3 courses of cyclophos-
phamide and etoposide, 9 of the patients had
delays after two of the chemotherapy courses.
Nine patients had vomiting for more than 12h,
four patients had diarrhoea up to 24h, nine
patients experienced transient cystitis and irritating
rashes occurred in 15 patients. Hair loss was
temporary. The area irradiated ranged from 63-
132cm2 (median 90cm2). No unexpected toxicity
was seen from the thoracic irradiation and no
patient declined treatment.
Discussion
The MLTG has developed a strategy over the past
4 years of short duration but intensive
chemotherapy for inoperable small cell lung cancer
(Thatcher et al., 1982a,b; 1984a,b). We have
reported previously median survivals of 11-12
months in 'limited stage disease', obtained with a 3-
month chemotherapy schedule using cyclo-
phosphamide, at escalating intrapatient dosages of
1.5-3.5gm-2 and thoracic radiotherapy (Thatcher
et al., 1982a; 1984b). The former studies also
included patients with a broader definition of
'limited stage disease' than is conventional. We
have treated those in 'limited stage' as patients who
have contra lateral neck nodes, pleural effusions
and marrow infiltration. It might be expected that
our results would therefore suffer, but the
prognostic significance of these metastatic sites is
uncertain (Greco et al., 1981; Hansen & Roth,
1983; Ihde et al., 1981).
In the present study and previously we found no
significant difference in survival when patients were
examined for these prognostic factors although a
multivariance analysis of the complete data base is
yet to be performed. The most important factor for
survival may well be the attainment of complete
response (Aisner et al., 1982). The current study
produced a similar median survival and is
comparable to the larger chemotherapy studies in
which the narrower definition of limited stage
disease was used, the chemotherapy being
continued for 1-2 years (Straus et al., 1983; Greco
et al., 1981; Hansen & Roth, 1983; MRC Lung
Cancer Working Party, 1979; Cortes Funes et al.,
1982; Souhami et al., 1984).
Furthermore the coexistence of chronic
obstructive airways disease in the majority of our
patients and low performance status before
treatment, would contribute to 'non cancer related
deaths' and adversely affect the long term survival
figures. We did not routinely give prophylactic
brain irradiation as our relapse data in the current
study and previously did not indicate a large group
of patients dying from cerebral metastasis as the
sole site of relapse (Thatcher et al., 1984b). Survival
from relapse was short and was considered to be
related to the tumour burden at relapse rather than
the subsequent chemotherapy given to only a
minority of these patients.
Greater than standard dosages of alkylating
agents including cyclophosphamide (occasionally
with marrow transplantation) have also been used
by other groups in an attempt to take advantage of
any dose response relationship (Greco et al., 1981;
Cohen et al., 1977; Souhami et al., 1983). Although
there is yet no obvious survival improvement in the
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t1he majority of complete responses noted clinically
and radiologically were confirmed by repeat
bronchoscopy. A more durable response and
corresponding longer survival may be expected for
a minority of these patients. Our updated crude 2
year survival from previous studies (Thatcher et al.,
1982a; 1984b) of 15% is somewhat less than the
17-20% average 2 year disease free survival quoted
from pooled studies, usually of small patient
numbers (Straus et al., 1983; Greco et al., 1981).
However survival in the larger studies
particularly from European groups of classical
limited stage disease patients are similar to those of
the MLTG (Hansen & Roth, 1983; MRC Lung
Cancer Working Party, 1979; Souhami et al., 1984).
An important consideration other than the
obvious benefit of a short treatment regimen for
patients, was the improvement in the patient's
general condition and breathing status noted at the
end of treatment. The expectation of some degree
of bone marrow suppression argued for the careful
monitoring of patients during treatment. Open
access to the treatment team was encouraged and
doubtless increased the frequency of antibiotics
prescribed. This facility rescued patients who would
have otherwise died of neutropenia and infection,
the result being few treatment related deaths.
Further development is clearly required to improve
the complete response and therefore the survival.
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